Loading patent…
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Institut Pasteur de Lille, Centre National de la Recherche Scientifique (CNRS), Universitë{umlaut over ( )}de Lille, Centre Hospitalier Regional Universitaire De Lille
InventorsLaurence Cocquerel-Deproy, Claire Montpellier, Jean Dubuisson, Anne Goffard
Estimating the term…
Hepatitis E virus (HEV) is responsible for over 50% of acute viral hepatitis cases worldwide. The inventors have now identified the precise sequence of infectious particle-associated ORF2 capsid protein. Strikingly, their analyses revealed that in infected patients, HEV produces three forms of the ORF2 capsid protein: ORF2i, ORF2g and ORF2c. The ORF2i protein is associated with infectious particles whereas ORF2g and ORF2c proteins are massively produced glycoproteins that are not associated with infectious particles and are the major antigens present in HEV-infected patient sera. Accordingly, the ORF2i and ORF2g proteins are thus the subject matter of the present invention as well as antibodies specific for the proteins and diagnostic assays (e.g. ELISA) for the diagnosis of Hepatitis E virus infection.
An ORF2i polypeptide consisting of an amino acid sequence as set forth in SEQ ID NO:1;
A nucleic acid molecule encoding for an ORF2i polypeptide consisting of the sequence set forth by SEQ ID NO:
Dependencies are inferred from the claim text.